Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors Abstract #990

Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.
Aim(s): However, the question is when to stop treatment once tumor stabilization has been achieved.
Materials and methods: We report our single center experience in the treatment of 14 patients with neuroendocrine tumors of the pancreas with a combination of streptozotocin and 5-FU.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Joerg Schrader
Keywords: chemotherapy

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2189 Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract
Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Anna Pellat
#1183 Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line
Introduction: The development of new therapeutic strategies for patients with pancreatic neuroendocrine tumours is impaired by the paucity of suitable pre-clinical models. Although the two available tumour cell lines BON and QGP have a neuroendocrine phenotype, the proliferation rate is too high for a well differentiated neuroendocrine tumour.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Rhotert C, Fahl M, ...
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1553 A Novel In Vitro Model of a Highly Proliferative Pancreatic Neuroendocrine Neoplasia
Introduction: Transformation of well-differentiated neuroendocrine tumors into highly proliferative neuroendocrine neoplasms is a rare, but clinical relevant phenomenon. So far, it is unclear whether these tumors should be treated in analogy to neuroendocrine tumors or as bona fide neuroendocrine carcinoma.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Erbes J, Eggers C, ...
Keywords: cell line
#1573 Regulation of Neuroendocrine Differentiation by Growth Factor Induced Proliferation in a Well-differentiated Pancreatic Neuroendocrine Tumor Cell Line
Introduction: The regulation of neuroendocrine differentiation in NET tumor cells is poorly understood. Clinical experience suggests a correlation between proliferation and neuroendocrine de-differentiation.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Fahl M, Eggers C, ...